Articles
Media
Publications
Conferences
CME/CE
Resources
Subscribe

Spotlight -

ZEISS Clinical Cases|

Heidelberg Engineering: Enhancing the Patient Journey

|Articles|February 11, 2009

Laser + IVTA for PDR and DME

Combined Laser and Intravitreal Triamcinolone for Proliferative Diabetic Retinopathy and Macular Edema: One-year Results of a Randomized Clinical Trial

Combined Laser and Intravitreal Triamcinolone for Proliferative Diabetic Retinopathy and Macular Edema: One-year Results of a Randomized Clinical Trial

, from the February 2009 issue of the

American Journal of Ophthalmology

.

Please click here to read the abstract.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Latest CME

(COPE Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care

(COPE Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care

Arjan Hura, MD; Neda Shamie, MD; Kristin Barnes, OD

Neurotrophic Keratitis Insights: An Interactive Corneal Sensitivity Testing Workshop

Neurotrophic Keratitis Insights: An Interactive Corneal Sensitivity Testing Workshop

John D. Gelles, OD, FAAO, FIAOMC, FCLSA, FSLS, FBCLA; John Hovanesian, MD, FACS

(CME Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care

(CME Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care

Jacob Lang, OD, FAAO; Selina R. McGee, OD, FAAO; Neda Shamie, MD

(COPE Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care

(COPE Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care

Jacob Lang, OD, FAAO; Selina R. McGee, OD, FAAO; Neda Shamie, MD

(CME Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care

(CME Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care

Arjan Hura, MD; Neda Shamie, MD; Kristin Barnes, OD

Retina Updates in Montréal

In-Person + Virtual Event

Retina Updates in Montréal

July 17, 2026

PER Global Perspectives: The TROP2-Targeted ADC Landscape in NSCLC and How to Interpret the Evidence

PER Global Perspectives: The TROP2-Targeted ADC Landscape in NSCLC and How to Interpret the Evidence

Solange Peters, MD, PhD; Benjamin P. Levy, MD; Tony S.K. Mok, MD, BMSc, FRCP(C), FRCP(Edin), FHKCP, FHKAM(Medicine), FASCO; Maurice Pérol, MD

Rapid Reviews in Retina™: Emerging Updates from Spring 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

Rapid Reviews in Retina™: Emerging Updates from Spring 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

SriniVas Sadda, MD, FARVO; Nathan Steinle, MD

Interventional Dry Eye: A Stepwise Treatment & Management Approach

Interventional Dry Eye: A Stepwise Treatment & Management Approach

Mark Schaeffer, OD, FAAO; Mile Brujic, OD, FAAO; Nate Lighthizer, OD, FAAO, FAAOMS; Selina R. McGee, OD, FAAO

(CME Track) Community Collaborative Connections™: Optimizing the Collaborative Care of Neovascular Retinal Disease in a New Age of Treatment

(CME Track) Community Collaborative Connections™: Optimizing the Collaborative Care of Neovascular Retinal Disease in a New Age of Treatment

Dilsher Dhoot, MD, FASRS; Jordana G. Fein, MD, MS; Deep Parikh, MD; Xiao-Yi (Ellie) Zhou, MD

(CME Track) Collaborating Across the Continuum™: Best Practices in Patient-Centric Team Management of XLRP

(CME Track) Collaborating Across the Continuum™: Best Practices in Patient-Centric Team Management of XLRP

Ramiro Maldonado, MD; Rebecca Nelson, MS, CGC; Robert A. Sisk, MD, FACS, FASRS

(CME Track) Rapid Reviews in Retina™: Emerging Updates from Summer 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

(CME Track) Rapid Reviews in Retina™: Emerging Updates from Summer 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

Mark R. Barakat, MD, FASRS; David Eichenbaum, MD, FASRS

(CME Track) A Forward Look at Anti-VEGF Therapies: A Paradigm Shift in Neovascular Retinal Disease Management

(CME Track) A Forward Look at Anti-VEGF Therapies: A Paradigm Shift in Neovascular Retinal Disease Management

David Almeida, MD, PhD, MBA; Margaret A. Chang, MD, MS; Arshad M. Khanani, MD, MA, FASRS; Jessica Randolph, MD

(CME Track) The Evolution of MacTel Management: Integrating Neuroprotective Therapies Into Clinical Practice

(CME Track) The Evolution of MacTel Management: Integrating Neuroprotective Therapies Into Clinical Practice

Dante Pieramici, MD, FASRS; Dean Eliott, MD; Robin A. Vora, MD; Charles C. Wykoff, MD, PhD, FASRS

Navigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVO

Navigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVO

SriniVas R. Sadda, MD, FARVO; Mark R. Barakat, MD, FASRS; David A. Eichenbaum, MD, FASRS

(CME Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

(CME Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

Stephen C. Pflugfelder, MD; Cecelia Koetting, OD, FAAO, DipABO

(COPE Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

(COPE Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

Stephen C. Pflugfelder, MD; Cecelia Koetting, OD, FAAO, DipABO

Navigating Ocular Toxicities: A Multidisciplinary Roadmap for Managing Adverse Events in Targeted Cancer Therapy

Navigating Ocular Toxicities: A Multidisciplinary Roadmap for Managing Adverse Events in Targeted Cancer Therapy

Basil Williams, MD; Maura Di Nicola, MD

Rapid Reviews in Retina™: Emerging Updates from Fall 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

Rapid Reviews in Retina™: Emerging Updates from Fall 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

John Kitchens, MD; Michael W. Stewart, MD

Trending on Ophthalmology Times Europe

Opuviz aflibercept biosimilar debuts in Europe for retinal disease treatment